AntibioTx, a clinical stage, pharmaceutical company targeting antimicrobial infections and microbiome-related disorders, has with the addition of two preclinical studies (Ocular Irritation and Phototoxicity) further strengthened ATx201’s safety profile for topical use.
The Ocular Irritation in vitro study evaluated the potential for causing eye damage using gold standard tests. ATx201 2%, 4% and Placebo were all classified as a non-irritant supporting the safety profile of ATx201 with regards to eye contact.
The Phototoxicity in vivo study determined the potential phototoxic effects of ATx201 Gel formulations when administered topically on the skin of hairless mice, followed by exposure to ultraviolet B, ultraviolet A and visible light.
The results provoked no cutaneous phototoxicity following topical dermal administration of the placebo or 2% or 4% ATx201. Dr. Morten Sommer, CSO of AntibioTx concluded: “The safety of ATx201 is of critical importance due to our focus on diseases that are very common in the pediatric population”.
This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.